AR122043A1 - Dosificación y administración del anticuerpo anti-ctla-4 activable - Google Patents

Dosificación y administración del anticuerpo anti-ctla-4 activable

Info

Publication number
AR122043A1
AR122043A1 ARP210101266A ARP210101266A AR122043A1 AR 122043 A1 AR122043 A1 AR 122043A1 AR P210101266 A ARP210101266 A AR P210101266A AR P210101266 A ARP210101266 A AR P210101266A AR 122043 A1 AR122043 A1 AR 122043A1
Authority
AR
Argentina
Prior art keywords
ctla
antibody
dosage
administration
activable anti
Prior art date
Application number
ARP210101266A
Other languages
English (en)
Inventor
Leonard P James
Michelle Brown
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR122043A1 publication Critical patent/AR122043A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona métodos de dosificación y administración de un anticuerpo anti-CTLA-4 activable, tal como un ipilimumab activable.
ARP210101266A 2020-05-12 2021-05-10 Dosificación y administración del anticuerpo anti-ctla-4 activable AR122043A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063023850P 2020-05-12 2020-05-12

Publications (1)

Publication Number Publication Date
AR122043A1 true AR122043A1 (es) 2022-08-03

Family

ID=76197648

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101266A AR122043A1 (es) 2020-05-12 2021-05-10 Dosificación y administración del anticuerpo anti-ctla-4 activable

Country Status (13)

Country Link
US (1) US20230192856A1 (es)
EP (1) EP4149544A1 (es)
JP (1) JP2023526232A (es)
KR (1) KR20230009432A (es)
CN (1) CN115515633A (es)
AR (1) AR122043A1 (es)
AU (1) AU2021270513A1 (es)
BR (1) BR112022022713A2 (es)
CA (1) CA3178649A1 (es)
IL (1) IL298126A (es)
MX (1) MX2022014113A (es)
TW (1) TW202207982A (es)
WO (1) WO2021231346A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024031032A1 (en) * 2022-08-05 2024-02-08 Bristol-Myers Squibb Company Anti-ctla-4 antibodies for treatment of kras mutant cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201902857SA (en) 2016-11-03 2019-05-30 Bristol Myers Squibb Co Activatable anti-ctla-4 antibodies and uses thereof
MX2019006340A (es) * 2016-12-07 2019-11-07 Agenus Inc Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.

Also Published As

Publication number Publication date
CA3178649A1 (en) 2021-11-18
BR112022022713A2 (pt) 2023-03-28
AU2021270513A1 (en) 2023-01-19
IL298126A (en) 2023-01-01
MX2022014113A (es) 2022-12-08
JP2023526232A (ja) 2023-06-21
WO2021231346A1 (en) 2021-11-18
US20230192856A1 (en) 2023-06-22
CN115515633A (zh) 2022-12-23
KR20230009432A (ko) 2023-01-17
EP4149544A1 (en) 2023-03-22
TW202207982A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
MX2022003572A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
CO2019009680A2 (es) Anticuerpo anti-gprc5d y molécula que comprende el anticuerpo
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
CL2022001752A1 (es) Compuesto de piridazinil-tiazolcarboxamida
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
DOP2016000133A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
MX2020007748A (es) Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas.
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
EA201992612A1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
DOP2023000107A (es) Compuesto de heteroarilcarboxamida
AR122043A1 (es) Dosificación y administración del anticuerpo anti-ctla-4 activable
CL2022001486A1 (es) Formulaciones de anticuerpos anti-pd-l1.
EA202091743A1 (ru) Вакцинация дендритными клетками параллельно с химиотерапией
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
EA202190504A1 (ru) Способы лечения псориаза